ESR1 and breast cancer: The combination of aCD40 and ICB (αPD1 and αCTLA-4), addressing both pre- and post-T cell activation defects, resulted in complete tumor clearance in the majority of TNBC and ER + tumor-bearing mice, representing unprecedented efficacy in an ER + murine breast cancer model.